Mibampator

Mibampator, known by its Eli Lilly code LY451395, is a biarylpropylsulfonamide positive allosteric modulator of AMPA receptors developed as a procognitive and behavior-modifying clinical candidate. Detailed electrophysiology showed that its modulatory efficacy is governed principally by the auxiliary transmembrane AMPA-receptor regulatory proteins, or TARPs, incorporated into a given receptor complex rather than by subunit identity or splice variation ^[1]. Receptors containing the stargazin TARP were slowed more than tenfold, whereas those with a different TARP were affected far less, meaning mibampator's action is regionally shaped by which auxiliary proteins dominate a synapse ^[1].

The most consequential clinical test of mibampator was a randomized, double-blind trial in outpatients with probable Alzheimer's disease and agitation or aggression ^[2]. Over twelve weeks, both mibampator and placebo improved on the primary Neuropsychiatric Inventory agitation and aggression subscale, with no significant difference between groups; among the secondary measures, mibampator was significantly better than placebo only on the Frontal Systems Behavior Inventory ^[2]. Adverse events were comparable to placebo. Commentators noted that caregiver effects, uncertain target engagement, and trial design may have contributed to the null primary result, and the study is frequently cited in reviews of pharmacological approaches to agitation in dementia ^[3].

Mibampator therefore occupies an important niche as one of the few AMPA potentiators to be tested in a controlled human behavioral trial. Although it did not succeed on its primary endpoint, its detailed molecular pharmacology and its clinical dataset make it a valuable reference compound for understanding the promise and the difficulty of AMPA-based therapeutics.

In its twelve-week Alzheimer's trial, mibampator at 3 mg orally showed an adverse-event profile comparable to placebo, with no excess mortality and generally acceptable tolerability in an elderly, vulnerable population. As an AMPA potentiator it carries the class-theoretical potential for overexcitation, and long-term safety was not established because development did not continue. It should be regarded as an investigational compound with a limited but reassuring short-term human safety record in one controlled study.

Mibampator was developed by Eli Lilly during the 2000s as part of a broad pharmaceutical effort to translate AMPA-receptor potentiation into treatments for cognitive and psychiatric disorders. It progressed to a registered randomized controlled trial for agitation and aggression in Alzheimer's disease, reported in 2012, and its molecular pharmacology was later dissected in comparison with the successor candidate PF-04958242 to understand what drives differential clinical efficacy among AMPA modulators.

In academic pharmacology mibampator is respected as a well-characterized AMPA potentiator and as a cautionary case study in the challenges of translating glutamatergic modulation into clinical benefit. It has essentially no consumer nootropic following because it was never marketed and its pivotal trial was negative on the primary endpoint. Its standing is that of an informative clinical-stage tool compound.